Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary DiseaseGlobeNewsWire • 12/04/19
Spero Therapeutics - Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 11/29/19
Spero Therapeutics (SPRO) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/30/19